Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.12
-0.4000-1.40%
Post-market: 28.130.0100+0.04%19:20 EDT
Volume:30.48M
Turnover:860.87M
Market Cap:159.88B
PE:37.01
High:28.59
Open:28.45
Low:28.08
Close:28.52
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.99
T/O Rate:0.54%
Dividend:1.72
Dividend Rate:6.12%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.88
PE(LYR):20.61

Loading ...

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Yesterday

Pfizer Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
2 hours ago

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
5 hours ago

Sector Update: Healthcare

MT Newswires Live
·
6 hours ago

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Yesterday

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Yesterday

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Yesterday

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Yesterday

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Yesterday

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Yesterday

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Yesterday

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Yesterday

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Yesterday

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Yesterday

NYSE Most Active Issues

Dow Jones
·
Yesterday

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

THOMSON REUTERS
·
Sep 29

Pfizer Gets Tax Penalty of 12.6 Million Rupees

Reuters
·
Sep 29